Boyds supports acquisition of UK-based oncology drug developer with scientific due diligence
![](https://boydconsultants.com/wp-content/uploads/2022/11/Website-news-cover-image-size-39.png)
Case study: Large company investments – Boyds supports the acquisition of UK-based oncology drug developer Background: The client was a large Asian-headquartered biopharmaceutical company, looking to grow through the purchase of multiple clinical and pre-clinical acquisitions. The target company with whom they wanted to engage with was a UK-based biotech company with assets in both […]
Assessment of novel vaccine technology triggers further investment
![](https://boydconsultants.com/wp-content/uploads/2022/11/Website-news-cover-image-size-38.png)
Case study: Assessment of novel vaccine technology triggers further investment Background: The client was a large multi-national fund, who has part ownership of a small biotech with a novel platform technology. The target company with whom they wanted to engage with was a European-based biotech company who were developing a novel technology platform to facilitate the […]